![Stephen Ma](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Ma
Finanzdirektor/CFO bei SCILEX HOLDING COMPANY
Vermögen: 17 431 $ am 31.05.2024
Aktive Positionen von Stephen Ma
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SCILEX HOLDING COMPANY | Investor Relations Kontakt | 01.01.2022 | - |
Finanzdirektor/CFO | 22.09.2023 | - | |
Public Communications Contact | 01.01.2022 | - | |
Unternehmenssekretär | 06.03.2024 | - | |
Comptroller/Controller/Auditor | 01.11.2022 | - |
Karriereverlauf von Stephen Ma
Ehemalige bekannte Positionen von Stephen Ma
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Anwita Biosciences, Inc.
![]() Anwita Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company located in the US. Anwita's lead product, exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. The American company specializes in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Anwita's core technology integrates structure-guided accukine cytokine evolution and accubody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile, and great development ability. The private company's unique product portfolio includes half-live extended exenokines, immune cell- or tumor cell-targeting mableukines, and bi-functional duoleukins. The company is also developing other cytokine-based therapeutics and antibody drug conjugates for the potential treatment of various cancers. | Geschäftsführer | 01.08.2019 | 01.01.2022 |
Finanzdirektor/CFO | 01.08.2019 | 01.01.2022 |
Ausbildung von Stephen Ma
San Jose State University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Director of Finance/CFO | 2 |
Comptroller/Controller/Auditor | 1 |
Investor Relations Contact | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SCILEX HOLDING COMPANY | Health Technology |
Private Unternehmen | 1 |
---|---|
Anwita Biosciences, Inc.
![]() Anwita Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company located in the US. Anwita's lead product, exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. The American company specializes in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Anwita's core technology integrates structure-guided accukine cytokine evolution and accubody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile, and great development ability. The private company's unique product portfolio includes half-live extended exenokines, immune cell- or tumor cell-targeting mableukines, and bi-functional duoleukins. The company is also developing other cytokine-based therapeutics and antibody drug conjugates for the potential treatment of various cancers. | Health Technology |
- Börse
- Insiders
- Stephen Ma
- Erfahrung